Systematic review and meta-analysis on targeted therapy in advanced pancreatic cancer.

摘要: Abstract Aim A systematic review and meta-analysis from literature has been performed to assess the impact of targeted therapy in advanced pancreatic cancer. Methods By searching different databases major cancer meetings proceedings, data all randomized clinical trials designed investigate molecular agents treatment were collected. The time-frame between January 2007 March 2015 was selected. Data on predefined end-points, including overall survival, progression-free survival terms Hazard Ratio response-rate extracted analyzed by a random effects model. Pooled analysis according DerSimonian Laird test. occurrence publication bias investigated through Begg's test visual inspection funnel plots. Results Twenty-seven for total 8205 patients selected included final analysis. significant benefit demonstrated anti-EGFR (HR = 0.880; 95% confidence interval (CI) 0.797–0.972; p = 0.011). In pooled no (OS: HR = 0.957; 95%CI 0.900–1.017; p = 0.153), or (PFS: HR = 0.908; 0.817–1.010; p = 0.075) targeted-based therapies as compared conventional treatments could be demonstrated. No advantage reported (OR RR = 1.210; 0.990–1.478; p = 0.063). plot showed evidence bias. Conclusion use does not translate into benefit. Therefore, our work highlights need identify predictive factors patient selection rationally trials.